10/07/2025
We have launched a €500,000 round on Capital Cell to launch the first oral microbiotherapy in Europe
We have recently launched a €500,000 investment round through Capital Cell, the leading equity crowdfunding platform in biomedicine.
The goal: to bring the first oral microbiota-based therapy, MBK-01, to the European market, a life-saving solution that restores the intestinal ecosystem with the potential to transform the treatment of recurrent infections such as Clostridioides difficile (CDI), decompensated liver cirrhosis, and acute diverticulitis.
A rethinking of medicine
‘We have been using antibiotics to kill bacteria for a century. Now we know that, in many cases, the key is not to eliminate them, but to maintain them,’ explains Patricia del Río, CEO of Mikrobiomik.
‘MBK-01 does not destroy: it rebuilds. And that opens up a new way of treating chronic infections, providing effective solutions for patients and curbing antimicrobial resistance.’
The impact is remarkable:
- 7 times more effective than standard antibiotics (fidaxomicin and vancomycin).
- 86.7% of patients cured, compared to only 12.5% with conventional therapy.
- 0 adverse effects in a phase III clinical trial. 100% safety.
More than 100 patients have already received this innovative therapy in more than 31 Spanish hospitals under compassionate use, confirming results in real-world practice.
An opportunity for investors who want to be part of the microbiome revolution
‘We want to open the door to new investors who share our vision: rebuilding gut health to solve complex diseases safely and sustainably. Today, you too can be part of this change,’ adds del Río.
Mikrobiomik’s round on Capital Cell will be open until 30 September 2025, with a minimum ticket of €1,000 and special rights for minority investors.
More information
👉 Invest now in Mikrobiomik: capitalcell.com/en/campaign/mikrobiomik/
